These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8576168)

  • 1. Biochemical and biophysical comparison of native and chemically synthesized phospholamban and a monomeric phospholamban analog.
    Mayer EJ; McKenna E; Garsky VM; Burke CJ; Mach H; Middaugh CR; Sardana M; Smith JS; Johnson RG
    J Biol Chem; 1996 Jan; 271(3):1669-77. PubMed ID: 8576168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and quantitation of phospholamban and its phosphorylation state using antibodies.
    Mayer EJ; Huckle W; Johnson RG; McKenna E
    Biochem Biophys Res Commun; 2000 Jan; 267(1):40-8. PubMed ID: 10623571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic null-cysteine phospholamban analogue and the corresponding transmembrane domain inhibit the Ca-ATPase.
    Karim CB; Marquardt CG; Stamm JD; Barany G; Thomas DD
    Biochemistry; 2000 Sep; 39(35):10892-7. PubMed ID: 10978176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The alpha-helical propensity of the cytoplasmic domain of phospholamban: a molecular dynamics simulation of the effect of phosphorylation and mutation.
    Paterlini MG; Thomas DD
    Biophys J; 2005 May; 88(5):3243-51. PubMed ID: 15764655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cysteine residues in structural stability and function of a transmembrane helix bundle.
    Karim CB; Paterlini MG; Reddy LG; Hunter GW; Barany G; Thomas DD
    J Biol Chem; 2001 Oct; 276(42):38814-9. PubMed ID: 11477077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the molecular form of cardiac phospholamban.
    Harrer JM; Kranias EG
    Mol Cell Biochem; 1994 Nov; 140(2):185-93. PubMed ID: 7898490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation by cAMP-dependent protein kinase modulates the structural coupling between the transmembrane and cytosolic domains of phospholamban.
    Li J; Bigelow DJ; Squier TC
    Biochemistry; 2003 Sep; 42(36):10674-82. PubMed ID: 12962492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-specific phosphorylation of a phospholamban peptide by cyclic nucleotide- and Ca2+/calmodulin-dependent protein kinases of cardiac sarcoplasmic reticulum.
    Karczewski P; Kuschel M; Baltas LG; Bartel S; Krause EG
    Basic Res Cardiol; 1997; 92 Suppl 1():37-43. PubMed ID: 9202842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of leucine 31 of phospholamban in structural and functional interactions with the Ca2+ pump of cardiac sarcoplasmic reticulum.
    Chen Z; Stokes DL; Jones LR
    J Biol Chem; 2005 Mar; 280(11):10530-9. PubMed ID: 15644311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concerted phosphorylation of the 26-kilodalton phospholamban oligomer and of the low molecular weight phospholamban subunits.
    Gasser JT; Chiesi MP; Carafoli E
    Biochemistry; 1986 Nov; 25(23):7615-23. PubMed ID: 2948562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for a phosphorylation-induced conformational change in phospholamban cytoplasmic domain by CD analysis.
    Terzi E; Poteur L; Trifilieff E
    FEBS Lett; 1992 Sep; 309(3):413-6. PubMed ID: 1387620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-reconstitution of phospholamban mutants with the Ca-ATPase reveals dependence of inhibitory function on phospholamban structure.
    Reddy LG; Autry JM; Jones LR; Thomas DD
    J Biol Chem; 1999 Mar; 274(12):7649-55. PubMed ID: 10075652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformation of the cytoplasmic domain of phospholamban by NMR and CD.
    Hubbard JA; MacLachlan LK; Meenan E; Salter CJ; Reid DG; Lahouratate P; Humphries J; Stevens N; Bell D; Neville WA
    Mol Membr Biol; 1994; 11(4):263-9. PubMed ID: 7711836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cysteine reactivity and oligomeric structures of phospholamban and its mutants.
    Karim CB; Stamm JD; Karim J; Jones LR; Thomas DD
    Biochemistry; 1998 Sep; 37(35):12074-81. PubMed ID: 9724519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fluorescence energy transfer method for analyzing protein oligomeric structure: application to phospholamban.
    Li M; Reddy LG; Bennett R; Silva ND; Jones LR; Thomas DD
    Biophys J; 1999 May; 76(5):2587-99. PubMed ID: 10233073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation-induced structural change in phospholamban and its mutants, detected by intrinsic fluorescence.
    Li M; Cornea RL; Autry JM; Jones LR; Thomas DD
    Biochemistry; 1998 May; 37(21):7869-77. PubMed ID: 9601048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation and phosphorylation change the oligomeric structure of phospholamban in lipid bilayers.
    Cornea RL; Jones LR; Autry JM; Thomas DD
    Biochemistry; 1997 Mar; 36(10):2960-7. PubMed ID: 9062126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial and dynamic interactions between phospholamban and the canine cardiac Ca2+ pump revealed with use of heterobifunctional cross-linking agents.
    Chen Z; Stokes DL; Rice WJ; Jones LR
    J Biol Chem; 2003 Nov; 278(48):48348-56. PubMed ID: 12972413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation-status of phospholamban and calsequestrin modifies their affinity towards commonly used antibodies.
    Huke S; Periasamy M
    J Mol Cell Cardiol; 2004 Sep; 37(3):795-9. PubMed ID: 15350852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct spectroscopic detection of molecular dynamics and interactions of the calcium pump and phospholamban.
    Thomas DD; Reddy LG; Karim CB; Li M; Cornea R; Autry JM; Jones LR; Stamm J
    Ann N Y Acad Sci; 1998 Sep; 853():186-94. PubMed ID: 10603946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.